A Novel Pathogenic Variant in RTEL1 Causes Dyskeratosis Congenita/Hoyeraal-Hreidarsson Syndrome: A Report of Two Cases.

J Pediatr Hematol OncolSep 30, 2026 (epub)

Michelle Nash, Alexandra Satty, Ariella Reiter et al.

✦ AI-curated · Sources linked

Case in brief

Two patients presented with severe immunodeficiency and very early-onset inflammatory bowel disease. Genetic testing identified the same novel homozygous RTEL1 variant, c.1670T>C (p.L557P). The authors concluded that the clinical findings in these patients support the variant’s pathogenicity and its association with a telomere biology disorder in the dyskeratosis congenita/Hoyeraal-Hreidarsson spectrum. The abstract does not report treatment or clinical resolution.

What made this case unusual

Both patients had severe immunodeficiency and very early-onset inflammatory bowel disease alongside the same novel homozygous RTEL1 variant, highlighting an atypical clinical presentation of a telomere biology disorder.

Diagnostic / clinical pearl

Severe immunodeficiency with very early-onset inflammatory bowel disease can accompany RTEL1-related telomere biology disorders, even when the classic dyskeratosis congenita features are not described.

Source

Published in J Pediatr Hematol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.